Italia markets closed

OLMA May 2024 12.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,3500+0,0500 (+16,67%)
In data: 12:48PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,3000
Aperto0,3500
Denaro0,1000
Lettera0,8500
Prezzo d'esercizio12,50
Scadenza2024-05-17
Min-Max giorno0,3500 - 0,3500
Contratto - Min-MaxN/D
Volume1
Open Interest58
  • GlobeNewswire

    Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

    Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023Olema will host an investor conference call at 8:00 a.m. ET on October 23, 2023 SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced an oral presen

  • GlobeNewswire

    Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

    Preclinical data to be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced new preclinical data regarding the discovery of novel compounds targeting KAT6, an epig

  • GlobeNewswire

    Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

    Amended clinical collaboration and supply agreement increases the palazestrant/ribociclib combination Phase 1/2 clinical study size to approximately 60 patients Expanded study supports the potential late-stage development of palazestrant in first-line advanced or metastatic breast cancer in combination with ribociclib SAN FRANCISCO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the